A case of chronic hepatitis C with sustained virological response by an intermittent use of low dose pegylated interferon

Kanzo/Acta Hepatologica Japonica

Volumn 49, Issue 10, 2008, Pages 470-475

  Shima, Chiharu ^a   Yamada, Akira ^a   Tsubosaka, Mako ^a   Sakurai, Motoko ^a   Nakatani, Kouji ^a   Kinoshita, Kazuo ^a   Kishida, Osamu ^a   Fujimoto, Takashi ^a   Minami, Yuzo ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Improvement of liver fibrosis; Intermittent use at low doses; PEG IFN

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHEMICAL ANALYSIS; CLINICAL FEATURE; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LOW DRUG DOSE; NEUTROPENIA; UNSPECIFIED SIDE EFFECT;

EID: 55249125932     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.49.470     Document Type: Article

References (18)

1. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-112
2. Nomura H, Kashiwagi Y, Hirano R, et al. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. Hepatol Res 2007; 37: 490-497
3. Akuta N, Suzuki F, Suzuki Y, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40: 688-696
4. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181
5. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-99
6. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-1402
7. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130
8. Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000; 20: 290-295
9. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17-27
10. Japanese source
11. Japanese source
12. Japanese source
13. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [strong neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002; 62: 94-100
14. Ikeda K, Arase Y, Saitoh S, et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: A large-scale long-term study in a single center. Intervirology 2006; 49: 82-90
15. Arase Y, Ikeda K, Suzuki F, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007; 79: 1095-1102
16. Japanese source
17. Reddy KR, Wreight TL, Pockros PJ, et al. Efficacy and Safety of Pegylated (40-kd) Interferonα-2a Compared With Interferonα-2a in Noncirrhotic Patients With Chronic Hepatitis C. Hepatology 2001; 33: 433-438
18. Ferraro D, Giglio M, Bonura C, et al. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. J Viral Hepat 2008; 15: 66-70